Meeting ReportOncology: Clinical Therapy and Diagnosis
Metabolic parameters by 18F-FDG PET/CT and peripheral blood biomarkers are associated with outcomes in patients with NSCLC under Immune Checkpoint Inhibitors treatment: the Immune-Metabolic-Prognostic Index (IMPI).
Angelo Castello, Luca Toschi, Fabio Grizzi, Sabrina Rossi, Dorina Qehajaj and Egesta Lopci
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 81;
Angelo Castello
4Department of Nuclear Medicine Humanitas Clinical and Research Hospital-IRCCS Rozzano (MI) Italy
Luca Toschi
5Department of Oncology Humanitas Clinical and Research Hospital-IRCCS Rozzano (MI) Italy
Fabio Grizzi
3Humanitas Clinical and Research Hospital-IRCCS Rozzano, Milan Italy
Sabrina Rossi
5Department of Oncology Humanitas Clinical and Research Hospital-IRCCS Rozzano (MI) Italy
Dorina Qehajaj
2Humanitas Clinical and Research Hospital-IRCCS Rozzano (MI) Italy
Egesta Lopci
1Humanitas Clinical and Research Hospital-IRCCS Rozzano Italy
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
Metabolic parameters by 18F-FDG PET/CT and peripheral blood biomarkers are associated with outcomes in patients with NSCLC under Immune Checkpoint Inhibitors treatment: the Immune-Metabolic-Prognostic Index (IMPI).
Angelo Castello, Luca Toschi, Fabio Grizzi, Sabrina Rossi, Dorina Qehajaj, Egesta Lopci
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 81;
Metabolic parameters by 18F-FDG PET/CT and peripheral blood biomarkers are associated with outcomes in patients with NSCLC under Immune Checkpoint Inhibitors treatment: the Immune-Metabolic-Prognostic Index (IMPI).
Angelo Castello, Luca Toschi, Fabio Grizzi, Sabrina Rossi, Dorina Qehajaj, Egesta Lopci
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 81;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.